Deutsche Bank downgraded ImmunoGen (IMGN) to Hold from Buy with a price target of $31, up from $25, after AbbVie (ABBV) announced an acquisition deal at $31 per share, or $10.1B deal value. Given AbbVie’s minimal commercial presence in solid tumors, the firm doesn’t anticipate the FTC to scrutinize the deal and it also does not anticipate any competing offers.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
- AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker
- ImmunoGen downgraded to Hold from Buy at Jefferies
- ImmunoGen downgraded to Hold from Buy at Canaccord
- ImmunoGen downgraded to Neutral from Buy at H.C. Wainwright
- ImmunoGen downgraded to Hold from Buy at Truist
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue